ATE301457T1 - Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor - Google Patents

Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor

Info

Publication number
ATE301457T1
ATE301457T1 AT96918465T AT96918465T ATE301457T1 AT E301457 T1 ATE301457 T1 AT E301457T1 AT 96918465 T AT96918465 T AT 96918465T AT 96918465 T AT96918465 T AT 96918465T AT E301457 T1 ATE301457 T1 AT E301457T1
Authority
AT
Austria
Prior art keywords
inhibitor
cyclooxygenase
agent containing
lipoxygenase
lipoxygenase inhibitor
Prior art date
Application number
AT96918465T
Other languages
English (en)
Inventor
Peter C Isakson
Gary D Anderson
Susan A Gregory
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE301457T1 publication Critical patent/ATE301457T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96918465T 1995-06-12 1996-06-11 Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor ATE301457T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48947295A 1995-06-12 1995-06-12
PCT/US1996/010106 WO1996041626A1 (en) 1995-06-12 1996-06-11 Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor

Publications (1)

Publication Number Publication Date
ATE301457T1 true ATE301457T1 (de) 2005-08-15

Family

ID=23944013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918465T ATE301457T1 (de) 1995-06-12 1996-06-11 Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor

Country Status (9)

Country Link
US (1) US6136839A (de)
EP (1) EP0833622B8 (de)
JP (1) JPH11507670A (de)
AT (1) ATE301457T1 (de)
AU (1) AU6111796A (de)
CA (1) CA2224517A1 (de)
DE (1) DE69635048T2 (de)
ES (1) ES2247604T3 (de)
WO (1) WO1996041626A1 (de)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3201095A (en) * 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
JP2000504723A (ja) * 1996-02-13 2000-04-18 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ―２阻害剤および５―リポキシゲナーゼ阻害剤投与の免疫抑制効果
DK0880363T3 (da) 1996-02-13 2003-01-20 Searle & Co Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
AU726664B2 (en) * 1996-07-11 2000-11-16 Warner-Lambert Company Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
EP0975604B1 (de) * 1997-03-14 2004-07-21 Merck Frosst Canada & Co. Pyridazinone als inhibitoren von cyclooxygenase-2
PT971714E (pt) * 1997-04-03 2002-12-31 Searle & Co Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
EE200300169A (et) * 1997-04-18 2003-06-16 G.D. Searle & Co. Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südame-veresoonkonna haiguste ärahoidmiseks
DK1032575T3 (da) 1997-09-05 2003-10-20 Glaxo Group Ltd 2,3-diaryl-pyrazol(1,5-b)pyridazinderivater, deres fremstilling og anvendelse som cyclooxygenase 2 (COX-2) inhibitor
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
TW587079B (en) * 1998-09-25 2004-05-11 Almirall Prodesfarma Ag 2-phenylpyran-4-one derivatives
US7223772B1 (en) 1998-11-03 2007-05-29 Smithkline Beecham Corporation Pyrazolopyridine derivatives as selective cox-2 inhibitors
ATE261444T1 (de) 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
DE10001166A1 (de) * 2000-01-13 2001-07-19 Merckle Gmbh Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
IN191512B (de) * 2000-01-21 2003-12-06 Panacea Biotech
US6800297B2 (en) 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
US6589557B2 (en) * 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US6545019B2 (en) * 2000-07-13 2003-04-08 Bristol-Myers Squibb Company Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2001285334A1 (en) * 2000-08-29 2002-03-13 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
ATE301653T1 (de) * 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridine
JP2004515550A (ja) * 2000-12-15 2004-05-27 グラクソ グループ リミテッド 治療用化合物
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
WO2002072581A2 (en) * 2001-03-08 2002-09-19 Smithkline Beecham Corporation Pyrazolopyriadine derivatives
WO2002078700A1 (en) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapteutic compounds
WO2002078701A1 (en) * 2001-03-30 2002-10-10 Smithkline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
ES2266487T3 (es) 2001-04-10 2007-03-01 Smithkline Beecham Corporation Compuestos de pirazolopirina antivirales.
JP4489354B2 (ja) 2001-04-18 2010-06-23 ユーロ−セルティーク エス．エイ． スピロインデンおよびスピロインダン化合物類
IL158484A0 (en) 2001-04-18 2004-05-12 Euro Celtique Sa Nociceptin analogs
EP1385518B1 (de) 2001-04-18 2008-08-06 Euro-Celtique S.A. Benzimidazolon-verbindungen
RU2268883C2 (ru) 2001-04-18 2006-01-27 Эро-Селтик, С.А. Аналоги ноницептина и фармацевтическая композиция на их основе
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
ATE296826T1 (de) * 2001-04-27 2005-06-15 Smithkline Beecham Corp Pyrazolo(1,5)pyridinderivate
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
ATE337316T1 (de) * 2001-06-21 2006-09-15 Smithkline Beecham Corp Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US20040214834A1 (en) * 2001-09-07 2004-10-28 Kristjan Gudmunsson Pyrazolo-pyridines for the treatment of herpes infections
JP3605105B2 (ja) * 2001-09-10 2004-12-22 キヤノン株式会社 電子放出素子、電子源、発光装置、画像形成装置および基板の各製造方法
EP1432712B1 (de) * 2001-10-05 2006-05-17 SmithKline Beecham Corporation Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
JP2005516916A (ja) * 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
US7071335B2 (en) 2002-02-01 2006-07-04 Euro-Celtique S.A. 2-pyridinyl-1-piperazine therapeutic agents useful for treating pain
AU2003216920A1 (en) * 2002-04-08 2003-10-20 Glaxo Group Limited (2-((2-alkoxy)-phenyl)-cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
EP1927858B1 (de) 2002-04-29 2013-01-09 Euro-Celtique S.A. Konformativ eingeschränkte Peptide zur Bindung des ORL-1-Rezeptors
RS95304A (sr) * 2002-05-07 2006-12-15 Altana Pharma Ag. Nova kombinacija za tretman oboljenja disajnih puteva
PT1505964E (pt) * 2002-05-17 2008-02-28 Merckle Gmbh Compostos de pirrole anelados como inibidores da bomba de protão para o tratamento da úlcera
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
WO2004017917A2 (en) * 2002-08-26 2004-03-04 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
JP2006504728A (ja) 2002-10-03 2006-02-09 スミスクライン ビーチャム コーポレーション ピラソロピリジン誘導体系治療用化合物
CA2502357A1 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
GB0225548D0 (en) * 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7879833B2 (en) * 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
CA2514363A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
EP1631568A1 (de) * 2003-04-18 2006-03-08 Memory Pharmaceuticals Corporation Pyrazolderivate als phosphodiesterase-4-inhibitoren
EP1622630B1 (de) * 2003-05-07 2012-08-29 Osteologix A/S Strontium-kombinationsbehandlung zur prophylaxe/behandlung von knorpel- und knochenzuständen
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1641775T1 (sl) * 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
BR0318395A (pt) 2003-07-10 2006-08-01 Arturo Jimenez Bayardo método para preparar uma solução aquosa de meloxicam e a solução aquosa resultante
GEP20094676B (en) * 2003-07-24 2009-05-10 Euro Celtique Sa Piperidine compounds and pharmaceutical compositions containing them
EP1867644B1 (de) 2003-07-24 2009-05-20 Euro-Celtique S.A. Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
DE602004017316D1 (de) 2003-07-24 2008-12-04 Euro Celtique Sa Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen
WO2005012287A1 (en) * 2003-08-01 2005-02-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
PT1670482E (pt) * 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
SI1664016T1 (sl) * 2003-09-22 2009-04-30 Euro Celtique Sa Terapevtska sredstva, uporabna za zdravljenje bolečine
PL1664041T3 (pl) * 2003-09-22 2008-12-31 Euro Celtique Sa Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
US20060079566A1 (en) 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
GB0323585D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323584D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323581D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Novel compounds
DE10351035A1 (de) * 2003-10-31 2005-05-25 Merckle Gmbh Chemisch Pharmazeutische Fabrik Pharmazeutische Licofelone-Formulierung
DE602004031356D1 (de) * 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
PL1727801T3 (pl) * 2003-12-30 2009-08-31 Euro Celtique Sa Piperazyny użyteczne do leczenia bólu
CA2551909C (en) * 2004-02-12 2011-10-11 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
US20070134165A1 (en) * 2004-04-20 2007-06-14 Altana Pharma Ag Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient
GB0410121D0 (en) * 2004-05-06 2004-06-09 Glaxo Group Ltd Compounds
US20090035315A1 (en) * 2004-06-17 2009-02-05 Stephan Christgau Method of Improving Treatments in Rheumatic and Arthritic Diseases
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
JP4954085B2 (ja) * 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
JP2008526894A (ja) * 2005-01-10 2008-07-24 レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア Ｃｏｘ阻害剤および５−ｌｏｘ阻害剤の活性を助けるための可溶性エポキシドヒドロラーゼの阻害剤の使用
MX2007009888A (es) * 2005-02-17 2007-10-16 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2007028638A1 (en) 2005-09-09 2007-03-15 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
PT1951718E (pt) 2005-11-21 2012-05-21 Purdue Pharma Lp Compostos de 4-oxadiazolil-piperidina e as suas utilizações
NL2000351C2 (nl) * 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
JP2009525269A (ja) * 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
NZ569329A (en) 2006-01-30 2011-09-30 Transtech Pharma Inc Substituted imidazole derivatives and their use as PTPase inhibitors
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
EP2040698A4 (de) * 2006-07-14 2011-08-10 Shionogi & Co Oximverbindungen und ihre verwendung
ES2433118T3 (es) 2006-11-01 2013-12-09 Purdue Pharma Lp Compuestos de fenilpropionamida y uso de los mismos
EP2397477B1 (de) * 2007-01-16 2014-03-05 Purdue Pharma LP Heterocyclisch-substituierte Piperidinverbindungen und Verwendungen davon
US20080181876A1 (en) * 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
MX2009011601A (es) 2007-04-27 2009-11-10 Purdue Pharma Lp Agentes terapeuticos utiles para tratar el dolor.
CA2685266C (en) * 2007-04-27 2014-01-28 Purdue Pharma L.P. Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
US7853320B1 (en) 2007-05-31 2010-12-14 Purdue Pharma L.P. Transdermal device having mechanical assist for porator-to-skin contact
US8095213B1 (en) 2007-05-31 2012-01-10 Purdue Pharma L.P. Transdermal patch
US8214031B1 (en) 2007-05-31 2012-07-03 Purdue Pharma L.P. Switch for transdermal patch
EP2164326A4 (de) 2007-05-31 2012-05-09 Euro Celtique Sa Amidverbindungen und ihre verwendung
US8563732B2 (en) * 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
US8047399B1 (en) 2007-07-05 2011-11-01 Purdue Pharma L.P. Dispenser for transdermal devices
MX2010000465A (es) 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
MY150602A (en) 2007-08-31 2014-01-30 Purdue Pharma Lp Subtituted-quinoxaline-type piperidine compounds and the uses thereof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2009059307A1 (en) 2007-11-01 2009-05-07 Washington University In St. Louis Compositions and methods for treating pruritus
CN101878214A (zh) 2007-11-30 2010-11-03 普渡制药公司 苯并吗啡烷化合物
AU2009203549B2 (en) * 2008-01-08 2013-03-07 Purdue Pharma L.P. Proline Analogs as ligands for cannabinoid receptors for the treatment of pain
EP2346820B1 (de) * 2008-06-11 2013-02-13 Shionogi & Co., Ltd. Oxycarbamoylverbindungen und deren verwendung
TWI403506B (zh) * 2008-06-16 2013-08-01 Faes Farma Sa 用於治療急性和慢性發炎疾病之５－（４－甲磺醯基－苯基）－噻唑衍生物類
BRPI0916761A2 (pt) 2008-07-17 2018-02-14 Ap Pharma formulações analgésicas injetáveis de ação prolongada para animais
KR101333660B1 (ko) 2008-07-21 2013-11-27 시오노기세이야쿠가부시키가이샤 치환-퀴녹살린-형 가교-피페리딘 화합물 및 그의 용도
ES2449222T3 (es) 2008-07-30 2014-03-18 Purdue Pharma Lp Análogos de buprenorfina
ES2439767T3 (es) 2008-08-01 2014-01-24 Purdue Pharma Lp Compuestos de tetrahidropiridinilo y dihidropirrolilo y uso de los mismos
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
CA2757726A1 (en) 2009-04-02 2010-10-07 Shionogi & Co., Ltd. Acrylamide compounds and the use thereof
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
US20100273203A1 (en) * 2009-04-23 2010-10-28 Board Of Trustees Of The University Of Arkansas Methods and compositions for detecting metabolites
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US8410064B2 (en) * 2009-08-24 2013-04-02 The Board Of Trustees Of The University Of Arkansas Classical cannabinoid metabolites and methods of use thereof
US8883218B2 (en) * 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
EP2582666B1 (de) 2010-06-16 2014-08-13 Purdue Pharma L.P. Arylsubstituierte indole und ihre verwendung als kalzium-kanal-blocker
US9279003B2 (en) 2010-07-07 2016-03-08 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
AU2011303597A1 (en) 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
KR20130095772A (ko) 2010-10-05 2013-08-28 퍼듀 퍼머 엘피 나트륨 채널 차단제로서 퀴나졸린 화합물
EP3363435A1 (de) * 2010-11-01 2018-08-22 The Ohio State University Research Foundation Celecoxibderivate gegen staphylokokken
US9598447B2 (en) 2010-12-22 2017-03-21 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
EP2655330B1 (de) 2010-12-22 2016-02-10 Purdue Pharma LP Substutuierte pyridine als kaliumkanalblocker
US9095598B2 (en) 2010-12-28 2015-08-04 The Board Of Trustees Of The University Of Arkansas Stilbenoid derivatives and their uses
JP5580492B2 (ja) * 2011-03-01 2014-08-27 エヌファルマコン，エルエルシー Ｎ−（４−メトキシフェニル）−１−フェニル−１ｈ−ピラゾール−３−アミンおよび関連化合物の使用
SI2688403T1 (sl) 2011-03-23 2017-08-31 Trevena, Inc. Ligandi opioidnih receptorjev in metode uporabe in izdelave istega
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
US8957024B2 (en) 2011-07-27 2015-02-17 Washington University Composition and methods for reducing opioid-induced pruritus
AU2012293417A1 (en) 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
EP3255041A1 (de) 2011-09-02 2017-12-13 Purdue Pharma L.P. Pyrimidine als natriumkanalblocker
WO2013064884A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013064883A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
US9133131B2 (en) 2011-11-15 2015-09-15 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
AU2012324015A1 (en) 2011-12-01 2013-06-20 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
EP2788358B1 (de) 2011-12-08 2018-08-29 Purdue Pharma LP Quaternisierte buprenorphinanaloga
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
AR091027A1 (es) 2012-05-11 2014-12-30 Purdue Pharma Lp Analogos de benzomorfano y el usos de estos
US9718865B2 (en) 2012-07-27 2017-08-01 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
EP2917182B1 (de) 2012-11-09 2018-01-03 Purdue Pharma LP Benzomorphan-analoge und ihre verwendung
WO2014087226A1 (en) 2012-12-07 2014-06-12 Purdue Pharma L.P. Buprenorphine analogs as opiod receptor modulators
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
JP6182620B2 (ja) 2013-01-31 2017-08-16 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体およびその使用
WO2014138669A1 (en) 2013-03-07 2014-09-12 Mindlab LLC Pain medicine combination and uses thereof
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
US20160213659A1 (en) 2013-09-24 2016-07-28 George Sylvestre Treatment of burn pain by trpv1 modulators
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
BR112017017619A2 (pt) 2015-02-19 2018-05-08 Purdue Pharma Lp métodos e composições para diminuir esvaziamento gástrico
US10813894B2 (en) 2015-02-20 2020-10-27 The Regents Of The University Of California Methods of inhibiting pain
KR20180093930A (ko) 2015-12-14 2018-08-22 트레베나, 인코포레이티드. 통각과민증을 치료하는 방법
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
US20190358208A1 (en) 2016-09-13 2019-11-28 Mindlab LLC Medicine combinations and treatment of restless leg syndrome
EP3681479B1 (de) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Natriumhydrogencarbonat zur verwendung in der behandlung von gicht und verwandten erkrankungen
JP2021501210A (ja) 2017-10-30 2021-01-14 モントリオール ハート インスティテュート 血漿コレステロールの上昇を処置する方法
EP3713916A1 (de) 2017-11-20 2020-09-30 Kiakos, Konstantinos Aus 3,5-diarylidenyl-n-substituiertes-piperid-4-on abgeleitete inhibitoren der stat3-weg-aktivität und verwendungen davon
US11251635B2 (en) 2017-12-19 2022-02-15 Welch Allyn, Inc. Vital signs monitor with a removable and dischargable battery
JP7108041B2 (ja) 2018-01-24 2022-07-27 パーデュー、ファーマ、リミテッド、パートナーシップ 睡眠障害の治療及び予防
PL4124336T3 (pl) 2021-07-30 2024-02-26 Cannamedical Pharma Gmbh Plaster przezśluzówkowy obejmujący kannabinoid i/lub opioid
WO2024160792A1 (en) 2023-01-30 2024-08-08 Cannamedical Pharma Gmbh Improved transmucosal patch comprising a cannabinoid and/or an opioid

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472420A (en) * 1983-08-18 1984-09-18 Methodist Hospital Of Indiana, Inc. Method for treatment of shock
US4760086A (en) * 1985-02-27 1988-07-26 Merck & Co., Inc. N-alkenyl-3-hydroxybenzo[b]thiophene-2-carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
ATE49198T1 (de) * 1984-05-12 1990-01-15 Fisons Plc Antiinflammatorische 1,n-diarylpyrazol-3-amine, deren zusammensetzungen und verfahren zu deren herstellung.
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US4769461A (en) * 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US4873259A (en) * 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
US5242940A (en) * 1987-05-29 1993-09-07 Ortho Pharmaceutical Corporation Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
WO1988009675A1 (en) * 1987-06-05 1988-12-15 Medicis Corporation Inhibition of arachidonic acid metabolism
PL154186B1 (en) * 1987-07-15 1991-07-31 Wellcome Found Method for manufacturing arylic derivatives of the hydroxamic acid
US4870210A (en) * 1987-12-18 1989-09-26 American Home Products Corporation Aminoguanidine derivative as anti-inflammatory agents
US5112868A (en) * 1988-05-19 1992-05-12 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
JPH0288553A (ja) * 1988-07-14 1990-03-28 Wellcome Found Ltd:The 抗炎症性アリール誘導体
GB8927287D0 (en) * 1988-12-23 1990-01-31 Ici Plc Cyclic ether derivatives
US5234950A (en) * 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
WO1990008146A1 (en) * 1989-01-10 1990-07-26 Pfizer Inc. Anti-inflammatory 1-heteroaryl-oxindole-3-carboxamides
US5066668A (en) * 1989-06-09 1991-11-19 Warner-Lambert Co. Triazole derivatives of fenamates as antiinflammatory agents
JPH06759B2 (ja) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
WO1991008737A2 (en) * 1989-12-16 1991-06-27 Fisons Plc Pharmacologically active amide carboxylate derivatives
JPH0717589B2 (ja) * 1990-01-22 1995-03-01 ファイザー製薬株式会社 新規１，３―ジカルボニル化合物およびその組成物
JPH0729998B2 (ja) * 1990-01-22 1995-04-05 ファイザー製薬株式会社 新規ベンゾキノン化合物およびその組成物
US5017604A (en) * 1990-04-11 1991-05-21 Warner-Lambert Company Novel fenamic acid methyl hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US5220059A (en) * 1990-04-19 1993-06-15 Abbott Laboratories Lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
AU8205991A (en) * 1990-06-12 1992-01-07 Smithkline Beecham Corporation Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
US5476873A (en) * 1990-07-25 1995-12-19 Abbott Laboratories Acetylene derivatives having lipoxygenase inhibitory activity
ES2095325T3 (es) * 1990-07-25 1997-02-16 Abbott Lab Derivados de acetileno con una actividad de inhibicion de la lipoxigenasa.
JPH04134077A (ja) * 1990-09-21 1992-05-07 Taiho Yakuhin Kogyo Kk イソオキサゾール化合物
IE913655A1 (en) * 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
DE4037426A1 (de) * 1990-11-24 1992-05-27 Kali Chemie Pharma Gmbh Piperidinoalkylbenzoxazin- und -thiazin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ZA919797B (en) * 1990-12-13 1992-10-28 Smithkline Beecham Corp Bicyclo-5,6-dihydro-7h-pyrrolo-1,20-imidazol-7-ols and 7-ones
US5356898A (en) * 1991-01-31 1994-10-18 Warner-Lambert Company Substituted 4,6-di-tertiary-butyl 5-hydroxy-pyrimidines
US5177079A (en) * 1991-01-31 1993-01-05 Warner-Lambert Company 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
WO1992015543A1 (en) * 1991-03-05 1992-09-17 Tsumura & Co. Novel allyl alcohol derivative
EP0633254A1 (de) * 1991-05-01 1995-01-11 Taiho Pharmaceutical Co., Ltd. Neue isoxazolderivate und ihre salze
FR2677355B1 (fr) * 1991-06-06 1993-08-20 Bellon Labor Sa Roger Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5270319A (en) * 1991-09-09 1993-12-14 Warner-Lambert Company 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
WO1993005795A1 (en) * 1991-09-13 1993-04-01 Boron Biologicals, Inc. Method of combatting osteoporosis and other disease states in mammalian subjects, utilizing organic boron compounds
US5476944A (en) * 1991-11-18 1995-12-19 G. D. Searle & Co. Derivatives of cyclic phenolic thioethers
US5354865A (en) * 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0679157B1 (de) * 1993-01-15 1997-11-19 G.D. Searle & Co. 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2161544A1 (en) * 1993-04-27 1994-11-10 Simon Teanby Hodgson Cyclooxygenase and 5-lipoxygenase inhibiting n(3-biphenylyl- 1(s)-methyl-2-propenyl) acetohydroxamic acid derivatives
GB9308652D0 (en) * 1993-04-27 1993-06-09 Wellcome Found Anti-inflammatory compounds
CA2161789A1 (en) * 1993-05-13 1994-11-24 Jacques Yves Gauthier 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
GB9312204D0 (en) * 1993-06-14 1993-07-28 Zeneca Ltd Therapeutic composition
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5298521A (en) * 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
DE69422306T4 (de) * 1993-11-30 2000-09-07 G.D. Searle & Co., Chicago Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs

Also Published As

Publication number Publication date
WO1996041626A1 (en) 1996-12-27
EP0833622B1 (de) 2005-08-10
US6136839A (en) 2000-10-24
EP0833622B8 (de) 2005-10-12
JPH11507670A (ja) 1999-07-06
ES2247604T3 (es) 2006-03-01
DE69635048D1 (de) 2005-09-15
DE69635048T2 (de) 2006-02-16
EP0833622A1 (de) 1998-04-08
CA2224517A1 (en) 1996-12-27
AU6111796A (en) 1997-01-09

Similar Documents

Publication Publication Date Title
ATE301457T1 (de) Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
ATE322893T1 (de) Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten
IL138028A0 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical use
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
TR199801930T2 (xx) 6-Fenilpiridil-2-amin t�revleri.
DK0827537T3 (da) Chromatin-regulator-gener
EP0813544A4 (de)
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
ZA968785B (en) Snatch block pins.
DE69427485D1 (de) Verbindungen, zubereitungen und behandlung von allergien und entzündungen
WO1998018440A3 (fr) Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles
MY129782A (en) Novel medical use
PT1133296E (pt) Nova aplicacao terapeutica da nicergolina
ATE28188T1 (de) Antikonvulsive mittel.
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
EP1083914A4 (de) Behandlung der arthritis und anderer ähnlicher störungen
ATE213644T1 (de) Kombinationstherapie für die behandlung von arthritis erkrankungen
NO963988L (no) Hypokolesterolemiske-, antiatherosklerotiske-, og hypotriglyceridemiske mercaptoacetylamidderivater
PT1133297E (pt) Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina
GEU1998400Y (en) Ointment “Topokril” for Treating of Dermatitis
FR2708283B1 (fr) Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.
UA32146A (uk) Спосіб оцінки ефективності лікування пародонтита
BG100479U (en) Medicament for the local treatment of otitis
UA32314A (uk) Спосіб лікування некротичного панкреатиту
UA36485A (uk) Спосіб лікування генералізованого пародонтиту

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties